Vera Therapeutics (NASDAQ:VERA) Earns Buy Rating from Guggenheim

Guggenheim reaffirmed their buy rating on shares of Vera Therapeutics (NASDAQ:VERA – Free Report) in a research report released on Friday, Benzinga reports. They currently have a $56.00 price target on the stock. Several other brokerages have also commented on VERA. Raymond James raised Vera Therapeutics from an outperform rating to a strong-buy rating and […]

Related Keywords

Raymond James ,Maha Katabi ,Cantor Fitzgerald ,Barclays Plc ,Vanguard Group Inc ,Capital Partners ,Goldman Sachs Group Inc ,Vera Therapeutics Inc ,Vera Therapeutics ,Free Report ,Director Maha Katabi ,Sachs Group ,Get Free Report ,Vera Therapeutics Daily ,Nasdaq Vera ,Vera ,Medical ,Reiterated Rating ,Guggenheim ,